This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Duensing, A. Articles by Fletcher, J. A. Search for Related Content PubMed PubMed Citation Articles by Duensing, A. Articles by Fletcher, J. A.

Protein Kinase C (PKC) Expression and Constitutive Activation in Gastrointestinal Stromal Tumors (GISTs)

¹ Department of Pathology, Brigham and Women’s Hospital, Boston, Massachusetts; ² Department of Medicine, Oregon Health & Science University, OHSU Cancer Institute and Portland VA Medical Center, Portland, Oregon; ³ OHSU Cancer Institute and Department of Pathology, Oregon Health & Science University, Portland, Oregon; and ⁴ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts

KIT expression is a key diagnostic feature of gastrointestinal stromal tumors (GISTs), and virtually all of the GISTs express oncogenic forms of the KIT or PDGFRA receptor tyrosine kinase proteins, which serve as therapeutic targets of imatinib mesylate (Gleevec; Novartis, Basel, Switzerland). However, KIT expression can be low in PDGFRA-mutant GISTs, increasing the likelihood of misdiagnosis as other types of sarcoma. We report that the signaling intermediate protein kinase C (PKC) is a diagnostic marker in GISTs, including those that lack KIT expression and/or contain PDGFRA mutations. PKC is strongly activated in most GISTs and hence may serve, along with KIT/PDGFRA, as a novel therapeutic target.

This article has been cited by other articles:

				A. Trojan, M. Montemurro, M. Kamel, and G. Kristiansen Successful PDGFR-{alpha}/{beta} targeting with imatinib in uterine sarcoma Ann. Onc., November 1, 2009; 20(11): 1898 - 1899. [Full Text] [PDF]

				G. D. Demetri, M. C. Heinrich, J. A. Fletcher, C. D.M. Fletcher, A. D. Van den Abbeele, C. L. Corless, C. R. Antonescu, S. George, J. A. Morgan, M. H. Chen, et al. Molecular Target Modulation, Imaging, and Clinical Evaluation of Gastrointestinal Stromal Tumor Patients Treated with Sunitinib Malate after Imatinib Failure Clin. Cancer Res., September 15, 2009; 15(18): 5902 - 5909. [Abstract] [Full Text] [PDF]

				M. C. Heinrich, S. George, S. Bauer, and J. A. Fletcher Optimizing the Treatment of Gastrointestinal Stromal Tumors: The Roles of Tumor Genotyping, Imatinib Blood-level Testing, and New Therapeutic Strategies ASCO Educational Book, January 1, 2009; 2009(1): 694 - 699. [Abstract] [Full Text] [PDF]

				H E Lee, M A Kim, H S Lee, B L Lee, and W H Kim Characteristics of KIT-negative gastrointestinal stromal tumours and diagnostic utility of protein kinase C theta immunostaining J. Clin. Pathol., June 1, 2008; 61(6): 722 - 729. [Abstract] [Full Text] [PDF]

				M. C. Heinrich, C. L. Corless, C. D. Blanke, G. D. Demetri, H. Joensuu, P. J. Roberts, B. L. Eisenberg, M. von Mehren, C. D.M. Fletcher, K. Sandau, et al. Molecular Correlates of Imatinib Resistance in Gastrointestinal Stromal Tumors J. Clin. Oncol., October 10, 2006; 24(29): 4764 - 4774. [Abstract] [Full Text] [PDF]

				L Tornillo and L M Terracciano An update on molecular genetics of gastrointestinal stromal tumours. J. Clin. Pathol., June 1, 2006; 59(6): 557 - 563. [Abstract] [Full Text] [PDF]